# PCCTC #: c16-168 (NCT03012321)

> Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03012321
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Northwestern University
- Conditions: Prostate Cancer Metastatic Castration-Resistant; Abnormal DNA Repair; Metastatic Prostate Carcinoma; Stage IV Prostate Cancer
- Interventions: Olaparib; Abiraterone Acetate; Prednisone
- Enrollment: 70
- Primary outcome: Objective Progression Free Survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 97
- YouTube: 32
- Podcasts: 31
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=pcctc-c16-168-nct03012321

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03012321", "email": "<work email>"}; the inbox owner confirms by the emailed link.